## Abstract ## Background Pneumocystis carinii pneumonia (PCP) is a wellknown risk among patients with deficient Tβcell function such as children treated for acute lymphoblastic leukemia (ALL). The purpose of this study was to estimate the risk for PCP during maintenance treament (MT) to identify
Spontaneous improvement of pneumocystis carinii pneumonia in childhood acute lymphocytic leukemia
β Scribed by Ettinger, Lawrence J. ;Torrisi, John ;Wood, Beverly P. ;Anderson, Virginia M.
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 938 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Until recently, Pneumocystis carinii pneumonitis was the most common cause of death in patients with leukemia in remission. Prior to the advent of effective antimicrobial agents, this disease was virtually 100% fatal in the cancer patient undergoing immunosuppressive therapy. The spontaneous improvement of P carinii pneumonitis in a child with acute lymphocytic leukemia suggests a higher incidence of P carinii pneumonitis in immunocompromised patients than is commonly realized.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. Despite extensive studies of atovaquone in human immunodeficiency virus (HIV)βinfected patients, there is little information about its efficacy as a prophylactic agent for __Pneumocystis carinii__ pneumonia (PCP) in pediatric patients with cancer. Therefore, a retrospect
## Abstract The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m^2^ IV weekly Γ 4) and Adriamycin (40 mg/m^2^ IV weeks 1 and 3). These drugs we
## Abstract Soft agar culture studies of 43 immunologically characterized patients with childhood acute lymphocytic leukemia (ALL) are presented. The immunologic subsets studied include βnullββcell, preβBβcell, and Tβcell leukemias. Abnormal myelopoiesis, including high peripheral blood and low mar
From the Divisions of Clinical Pharmacology and Toxicology (M.B., D.M., G. K.